The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

Historically, RSV has been studied mainly in infants and older adults, but recent research shows that it also poses a ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read ...

"These findings support the widespread use of nirsevimab to prevent severe respiratory infections caused by RSV in young infants, highlighting its potential to substantially reduce the healthcare ...

The hospital has seen over 200 RSV admissions this winter, but a new preventative measure offers hope. "They came out with a vaccine for babies six months and younger, so that can definitely help ...

Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

The signs might be apparent in adults - but less noticeable in young infants. While RSV typically causes a mild, cold-like illness, it can also lead to severe illness such as bronchiolitis and ...

This winter, the respiratory syncytial virus (RSV) infection is spreading, leading to a shortage of preventive antibodies for infants and young children. Vaccines induce immune responses in the ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

From March 17, free immunisation for RSV will be made available to all newborn babies in NSW under an expanded program. From March 17, free immunisation for the virus will be made available to all ...